Nitroprusside
Sodium nitroprusside has profound vasodilating properties. Initial studies of nitroprusside encompassing angioplasty, stent deployment or rotational atherectomy on either SVGs or native vessels demonstrated highly significant, rapid and safe improvement of no-reflow by a variety of criteria.[43] No significant hypotension or other adverse clinical events were reported. In a small study,[44] IC bolus injection of nitroprusside as an adjunct to primary PCI improved angiographic TIMI flow by at least 1 grade in 9 of 11 patients (82%; p = 0.007). Treatment was uniformly safe.
J Invasive Cardiol. 2008;20(7):374-379. © 2008 HMP Communications
Cite this: Pharmaceutical Interventions for the Management of No-Reflow - Medscape - Jul 01, 2008.
Comments